Scott Kopetz, MD at MD Anderson discusses the FDA Approval Encorafenib) In Combination With Cetuximab For The Treatment Of Brafv600E-Mutant Metastatic Colorectal C Advertisement Based on BEACON CRC test results, BRAFTOVI plus cetuximab showed a median overall survival ( OS) of 8.4 months (95 percent CI: 7.5, 11.0) compared to 5.4 months (95 percent CI: … Continue reading Scott Kopetz, MD @skopetz @MDAndersonNews FDA Approves Braftovi® (Encorafenib) In Combination With Cetuximab For The Treatment Of Brafv600E-Mutant Metastatic Colorectal Cancer